BHCM
FBRX

Brevan Howard Capital Management’s Forte Biosciences FBRX Stock Holding History

Brevan Howard Capital Management’s Portfolio FBRX Stock Details FBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-14,020
Closed -$363K – 2217
2026
Q1 		$363K Buy
+14,020
New +$404K ﹤0.01% 1489

Other funds holding FBRX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
FAM
Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Brevan Howard Capital Management's FBRX Position: Q2 2026 in Review

Brevan Howard Capital Management sold out of Forte Biosciences (FBRX) in Q2 2026, closing a stake of 14,020 shares — an estimated $363K sold.

Brevan Howard Capital Management first reported a position in FBRX in Q1 2026 and held it in 1 quarter. The position peaked at $363K in Q1 2026. 86 funds tracked by Wall St. Rank hold FBRX as of Q2 2026.

  • Brevan Howard Capital Management reported no remaining Forte Biosciences position as of Q2 2026 after selling out during the quarter.
  • Brevan Howard Capital Management sold 14,020 Forte Biosciences shares in Q2 2026, an estimated $363K.
  • Brevan Howard Capital Management first reported a position in Forte Biosciences in Q1 2026 and held it in 1 quarter.
  • Brevan Howard Capital Management's Forte Biosciences position peaked at $363K in Q1 2026.
  • 86 funds tracked by Wall St. Rank held Forte Biosciences as of Q2 2026.

Based on Brevan Howard Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.